About Megan Blutfield

This author has not yet filled in any details.
So far Megan Blutfield has created 63 blog entries.

Conference: ASGCT Annual Meeting, 2022

2022-05-20T09:29:29-04:00Cell & Gene Therapy, Events|

Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.


Article: Cell & Gene Therapies: Opportunities for Innovation

2022-05-20T09:21:47-04:00Cell & Gene Therapy, Events|

In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.


Key Takeaways: World EPA Congress 2022

2022-05-16T16:09:14-04:00Cell & Gene Therapy, Events|

Did you miss our presentation at this year’s World EPA Congress in Amsterdam? Precision experts Richard Macaulay (VP, Global Pricing and Market Access) and David Carr (Director, Global Pricing and Market Access) presented “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” which analyzes the access success of launched gene therapies and draws best-practice learnings for future gene therapies.


On-Demand Webinar: Planning for the Commercialization of Advanced Therapies

2022-03-25T11:47:28-04:00Cell & Gene Therapy, Events|

In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?


Load More Posts